Leading the Way in Precision Medicine
An innovative company with deep scientific and clinical expertise, dedicated to developing precision oncology medicines that deliver the best outcomes for patients.
Anbogen Therapeutics is a clinical-stage biotech company dedicated to designing and developing precision oncology therapies to improve patients' lives. Founded by a group of exceptional scientists committed to bridging the gap between research and clinical development. Our mission is to create breakthrough science that transforms the lives of cancer patients.
Milestones
In July 2023, ABT-101 obtained the first crystal form patent in Taiwan
In June 2023, Anbogen filed a US provisional application for the crystal form of ABT-301
In February 2023, the US FDA formally approved the amendment to the Investigational New Drug (IND) clinical trial plan for ABT-101
In September 2022, the first patient was recruited for the ABT-101 clinical trial
In August 2022, Anbogen's laboratory, located in the National Biotechnology Research Park, was officially inaugurated
In March 2022, the TFDA approved the phase 1b/2 clinical trial of ABT-101 in Taiwan
In October 2020, Anbogen signed a license agreement for ABT-301 with Taipei Medical University
In April 2020, Anbogen signed a license agreement for ABT-101 with the National Health Research Institutes
Dr. Chuan Shih, Dr. Hsing-Pang Hsieh, and Dr. Tsu-An Hsu founded Anbogen Therapeutics, Inc.